HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of ocular tissues exposed to nitrogen mustard: beneficial effect of zinc desferrioxamine combined with steroids.

AbstractPURPOSE:
Exposure of the ocular surface to mustard gas chemical warfare leads to a destructive inflammatory reaction. Both steroids and a novel metalocomplex free radical scavenger, zinc desferrioxamine (Zn/DFO), have been shown to be effective separately in reducing ocular damage. The purpose of the present study was to investigate whether the effectiveness of both medications applied simultaneously is superior to the effectiveness of either one applied alone.
METHODS:
One eye in each of 52 rabbits was exposed to 2% nitrogen mustard (NM). Topical treatment with eye drops of a metal complex-zinc desferrioxamine (Zn/DFO)-combined with dexamethasone phosphate (0.1%), was compared with the administration of saline or treatment with Zn/DFO or dexamethasone alone. Eight eyes (four animals) that were not exposed to NM served as the control. Examiners masked to the treatment groups assessed the extent of ocular injury and the response to treatment using clinical, histologic, and biochemical criteria.
RESULTS:
Treatment with the combination of Zn/DFO and dexamethasone was significantly more effective than was dexamethasone or Zn/DFO alone in reducing NM injury to ocular anterior segment structures. In combination-treated eyes, corneal re-epithelization was faster, corneal neovascularization was less severe, and intraocular pressure was not as severely elevated as in the saline or the Zn/DFO- or dexamethasone-alone groups. In addition, systemic antioxidant status was better conserved in the combination-treated animals.
CONCLUSIONS:
The findings suggest that the combination of topically applied Zn/DFO and dexamethasone, by virtue of their additive inhibitory effects on free radical formation and inflammation, should be considered as a basis for the treatment of ocular mustard gas injuries.
AuthorsYair Morad, Eyal Banin, Edward Averbukh, Eduard Berenshtein, Alexey Obolensky, Mordechai Chevion
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 46 Issue 5 Pg. 1640-6 (May 2005) ISSN: 0146-0404 [Print] United States
PMID15851563 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chemical Warfare Agents
  • Free Radical Scavengers
  • Glucocorticoids
  • Organometallic Compounds
  • Reactive Oxygen Species
  • zinc-desferrioxamine
  • Mechlorethamine
  • Dexamethasone
  • Oxidoreductases
  • Methionine Sulfoxide Reductases
  • methionine sulfoxide reductase
  • Deferoxamine
  • Zinc
Topics
  • Animals
  • Atrophy
  • Burns, Chemical (drug therapy, etiology, pathology)
  • Chemical Warfare Agents (toxicity)
  • Corneal Diseases (chemically induced, drug therapy, pathology)
  • Corneal Neovascularization (chemically induced, drug therapy, pathology)
  • Corneal Opacity (chemically induced, drug therapy, pathology)
  • Deferoxamine (therapeutic use)
  • Dexamethasone (therapeutic use)
  • Drug Therapy, Combination
  • Eye Burns (chemically induced, pathology)
  • Free Radical Scavengers (therapeutic use)
  • Glucocorticoids (therapeutic use)
  • Intraocular Pressure
  • Iris (pathology)
  • Mechlorethamine (toxicity)
  • Methionine Sulfoxide Reductases
  • Organometallic Compounds (therapeutic use)
  • Oxidoreductases (metabolism)
  • Rabbits
  • Reactive Oxygen Species (antagonists & inhibitors)
  • Wound Healing (drug effects)
  • Zinc

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: